LITTLE KNOWN FACTS ABOUT INTERLEUKIN-2 THERAPY.

These increasing cells were distinguished from increasing B cells by the absence of EBV, which could boost the extensive-term progress of B cells. These findings have been immediately accompanied by experiments, each in mice and people, demonstrating that supernatants derived from lectin-stimulated ordinary lymphocytes could maintain The expansion